<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 324 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page323.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=324">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 324 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 324</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=324"><img src="../thumb/324.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Endocrine System - 19.1.1                                                      2020-04 / 287
       reduc.in pres.of ren/hepat.impairm., not to be given IV except for   Drug interactions: Oral hypoglycaem. agents/ MAOI/ beta-block./  Drug interactions: Oral antidiabet.agents/ACE-inhibit./disopyra-
       Humulin R., pregn.& lactat., dos.adjustm.with incr. phys.activ./diet   ACE inhibit./salicylates & alcoh. reduc.requirem., thiazid./glucocor-  mide/fibrates/fluoxetine/ MAOI/, pentoxifylline/propoxyphene/sa-
       chang., concom.thiazolidinediones assoc. with incr.risk of oed.&   tic./ thyroid hormon./beta-sympathomim./growth hormon.& danazol   licylates & sulfonamide antibiot.may enhanc.bld.gluc.low.eff., corti-
       HF esp.underly.card. dis.     incr.requirem., beta-block.may mask hypoglycaem. sympts.& delay   coster./danazol/diazoxide/diuret./glucagon/ isoniazid/oestrog./pro-
       Drug interactions: ß-block.may mask sympt.of insulin induc.hy-  hypoglycaem. recovery, octreotide & lanreotide incr. & decr. re-  gestog./phenothiaz.deriv./ somatropin/sympathomimet.& thyroid
       poglycaem., insul.requirem.incr.by agents with hyperglycaem.activ.  quirem., alcoh.intensif.& prolongs hypoglycaem. eff.  hormon. may reduc.bld.gluc.low.eff., ß-block./clonid/Li & alcohol
       eg.OC’s/ corticoster /thyroid replacem.ther., insul.requirem. reduc.   may either potent.or weak.bld.gluc.low. eff., pentamid.may cause
       by drugs with hypoglycaem.activ.eg. oral anti-diabet.agents/sa-  NOVOMIX 30, Novo Nordisk  hypoglycaem.follow.by hyperglycaem., signs of adrenerg.counter-
       licylates/sulpha antibiot./ MAOI/ ACE inhibit./angiotens.II recept.  Sol.insulin aspart/ protamine-crystall.insulin aspart in 30/70 ratio     regulat. reduc./absent und.influence of sympatholyt.
       block./ ß-adrenerg. block.    (recombin.DNA orig.), Saccharomyces cerevisiae.  PROTAPHANE HM (ge), Novo Nordisk
                                     Indications: Insulin depend.diabetes mellit.
       INSUMAN COMB, Sanofi-Aventis  (S3) INJ, 35/21.1/0031. 100 IU/ml  Biosynthet. human isophane insulin susp.of monocompon.
       Biphas.isophane human insulin (rDNA origin). 30% sol.insul., 70%   702086-003: 5x3 ml multidos.FlexPen, R654,01  isophane insulin
       isophane insul.               702089-003: 5x3 ml multidos Penfill cartr. R673,93  Indications: Diabet.mellit.
       Indications: Diab.mellit.     Dosage: Indiv. as need. Admin.SC. Usual.betw. 0,5-1,0 U/kg/day.   (S3) INJ. W/21.1/290. 100 u/ml.
       (S3) 30/70 SUSP.FOR INJ, 36/21.1/0080. 100 IU/ml  Recomm.2x/day when reach. 30 U/day. Contin.dos.titrat as need.   733482-007: 1x 10 ml vial, R337,93
       710299-001: 5x3 ml cartridge, R561,39  Admin. to childr./adolesc.≥10 yrs. May be giv.as monother. in pts.  700183-001: 5x3 ml, Flexpen dispos.syr., R632,97
       Dosage: Use with OptiSet (dispos.pen) OR OptiPen Pro (non-  with Type 2 diab.when need.  Dosage: Indiv.  Admin. SC usuall.betw. 0,3 -1,0  IU/kg/day.
       dispos.pen).                  Contraindications: Hypoglycaem., IV inj.  Ref.to prod.lit.for various device use
       Indiv.accord.to physic.activ.& life-style. Admin. SC 25-40 mins.  Side effects: Hypoglycaem., oed.& refract. anomal., loc./gen.  Contraindications: Hypoglycaem.
       bef.meal.                     hypersens./anaphylact.reacts., lipodystrophy, periph.neuropathy,   Side effects: Hypoglycaem., anaphylact./ loc.reacts., rash, ur-
       Contraindications: IV use, use in infus.pumps, ext./implant.insulin   diab.retinopathy.  ticar., diab.retinopathy, periph. neuropathy, lipodystrophy, oed.,
       pumps, no exper.in pregn.,    Warnings and special precautions: Monit. HF S&S/ mass   refract.disords.
       Side effects: Hypoglycaem., tempor.vis. impairm. with mark.change   gain/oed.when pioglitazone used concom., discont.pioglitazone   Warnings and special precautions: Congest.HF poss. with pi-
       in glycaem.control, lipodystrophy, loc.reacts., hypersens.reacts., in-  in case of card.funct. deteriorat. signs, insul.dos.adjustm.poss.  oglitazone & insul.combinat., discont. pioglitazone if deteriorat .in
       sulin antibody format., Na retent.& oed.  necess.to correct hypo-/hyperglycaem. in case insul. antibod.   card.sympt.occur, usual hypoglycaem.warn.signs poss.chang., pt.
       Special precautions: Cont.use in hypersens. pts. where no   form., hypoglycaem.warn.signs poss.chang.,  poss. hyperglycaem./  transf. to new type/brand insul.und.strict med. supervis., poss.hy-
       better tol.prep.avail.only und.close medic.supervis.& in conjunct.  diab.ketoacidos.with inadeq.dos./ treatm. discontin., pt.tfd.to new   perglycaem./diab.ketocidos.with inadeq. dos./treatm.discont., sev.
       with anti-allerg. tretm. when necess., intraderm.skin test.recomm.   type/brand insul. und. strict supervis., limit.data in childr.6-9 yrs.,   hypoglycaem.may lead to unconsciousn.&/convuls.poss.result.in
       where anim.insulin allergy pres., insulin requirem. reduc.in pres.of   travel. betw.diff. time zones, ren./hepat.impairm., monit. dur.preg./  brain funct.impairm./death, nev.use IV/in infus. pumps.
       ren./hepat.impairm., where hypoglycaem.episod.of clinic.signif.eg.   contempl.pregn.   Drug interactions: Oral hypoglycaem.agents/ MAOIs/non-
       coron.arter./brain bld.vess.stenos./proliferat. retinopathy, condits.  Drug interactions: Oral hypoglycaem.agents/ octreotide/MAOI/  select.ß-blocks./ACE inhibit./ salicylat./ alcoh.poss.reduc.insul.
       where hypoglycaem.warn. sympts. dimin., fact.incr.susceptibil.to   non-select.ß-adrenerg.block. agents/ ACE inhib./salicylat/alcohol/  requirem., OC’s/ thiaz./glucocortic./thyroid hormon./ sympathom-
       hypoglycaem., intercurr.illn., other insulin transf.  anabol. steroids & sulphonam.reduc.insul.requirem., OC’s/ thiazides/  imets./ growth hormon.& danazol may incr. insul.requirem., ß-blocks.
       Drug interactions: Oral antidiabet./ACE-inhibit. / disopyramide/  glucocortic./thyroid hormones/ sympathomimet. & danazol.incr. in-  poss.mask hypoglycaem., ocreotide may decr./incr.insul. requirem.,
       fibrates/fluoxetine/MAOI’s/ pentoxifylline/ propoxyphene/salicy-  sul. requirem., ß-block.poss.mask hypoglycaem.sympts., alcoh. in-  alcoh.intens.& prolongs hypoglycaem. eff.
       lates & sulphonam. antibiot.enhanc.bld.gluc.low.eff., corticoster./   tens. & prolongs hypoglycaem.eff.
       danazol/diazoxide/diuret./glucagon/ isoniazid/ oestrog./progestog./  RYZODEG, Novo Nordisk
       phenothiaz. derivat./ somatrophin/sympathomimet.agents & thyroid   NOVORAPID, Novo Nordisk  70% soluble insulin degludec, 30% soluble insulin aspart.
       hormon.reduc.bld.gluc.low.eff., ß-block./ clonidine / Li & alcoh.may   Insulin aspart.  Indications: Adult diab.mellit.treatm.as basal add on to co-med.
       potent.or weak.bld. gluc. low.eff., hypoglycaem.poss.follow.by hy-  Indications: Insulin req.diab.mellit.  in inadeq.control.pts.
       perglycaem. with pentamidine, adrenerg. counter-regulat.signs re-  (S3) SOL FOR INJ, 34/21.1/0160. 100 u/ml.  (S3) SOL.FOR INJ., 47/21.1/0165
       duc./absent with sympatholyt. prods.  897767-001: 5x3 ml multi.dos.FlexPen, R547,48  722292-001: 100 units/ml, 1x3 ml penfills, R197,44
                                     897775-004: 5x3 ml multi.dos.Penfill.cart., R491,89  722292-002: 100 units/ml, 5x3 ml penfills, R987,23
       LANTUS, Sanofi-Aventis        707927-0001: 10 ml multi dos.vial, R347,98  Dosage: Admin.SC only 1-2xdly with main meals. 1 Ryzodeg unit
       Insulin glargine, correspond.to 100 U human insulin/ml.  Dosage: Admin.as contin.subcut.insulin infus. with pump syst./  = 1 IU human insul.& 1 unit of all other insul.analog. In type 2 diab.
       Indications: Diab.mellit.when insulin reqd.  SC inj/IV. Immed.bef.or aft.a meal due to fast onset of act. Use in   mellit.use with oral anti-diab.prod.appprov.for use with insul., with or
       (S3) SOL.FOR INJ, 34/21.1/0248. 100 U/ml  combinat.with intermed.-act./ long-act.insul.admin.once dly. In meal   without bolus insulin. In type 1 diab.mellit combin. with short-/rapid
       700310-001: 1x10 ml vial, R508,85  relat. treatm. 50-70% of requirem.provid.by NovoRapid and bal.by   act.insul at remain. meals. Indiv.dos. Insul.dos.adjustm.poss.necess.
       700308-001: 5x3 ml cartr.for use with a reusable (Pen), R763,32  intermed./long.act.insul.
       709860-001: Dispos.pen, 5x3 ml,(Solostar) R836,05  May be used dur.pregn.,lactat.  if pts. undertak.incr. physic. activ./change diet/dur. concomit.illn.
                                                                  Type 2 diab.mellit: Init. Recomm.tot.dly start.dos 10 U once dly
       Dosage: Indiv.                Indiv.dos. Adults & childr.2 yrs.& old : Usual. betw. 0,5-1,0 U/
       Contraindications: Safety & effic.not est.in childr. &lt; 6yrs old, dia-  kg/day  with meal.follow.by indiv.adjustm.
                                                                  Type 1 diab.mellit: Admin.once dly.at mealt.with short-/rapid act.
       bet.ketoacidos., no info on use in pregn. & lactat.  Contraindications: Hypoglycaem.  insul.at remain.meals adjust. indiv. Recomm.start.dos: 60-70% of
       Side effects: Hypoglycaem., poss.vis.impairm. with mark.change   Side effects: Hypoglycaem., loc.reacts., refract. anomal., lipodys-
       in glycaem.contr., lipodystrophy, loc.reacts., allerg.reacts., insul. an-  trophy if inj.sites not rotat., periph. neuropathy, potent.life-threat.  tot.dly.insul. requirem.
                                                                  See manufact.lit.when tfd.from other insul. medicin. prod
       tibod.product., rarely sod.retent.& oed.  gen.hypersens. reacts.
       Special precautions: Prolong.act.depend.on SC inj., rotate inj.  Warnings and special precautions: Monit.HF S&S/ mass gain/  Contraindications: Pregn., do not admin.IV/IM/in insul.infus.
                                                                  pumps.
       sites, IV admin.could result in sev. hypoglycaem., do not dil/mix.  oed.if used in combin.with pioglitazone, discont.pioglitazone in case
       with other insul., see lit.regard.change over from other insulin(s),   of card. funct. deteriorat.signs, dos.adjustm. poss.necess. to correct   Side effects: Very common: Hypoglycaem. Common: Inj.site re-
       metabol. monit.recomm.dur.changeover & init. wks. thereaft., pres.  hypo-/hyperglycaem.in case insul. antibod. form., hypoglycaem.  acts. Uncommon: Periph. oed. Rare: Hypersens., urticar.
       of insul.antibod.may req.dos. adjustm., where hypoglycaem.episod.  warn.signs poss. chang., poss.hyperglycaem./diab.ketoacidos.  Warnings and special precautions: Hypoglycaem., decr.sensitiv.
       of clinic. signific., circumst.where warn.sympts.of hypoglycaem. di-  with inadeq. dos./treatm.discont., tfd.pts.to other types/ brands   to usual hypoglycaem. warn.sympts.in pts.with improv.bld.gluc.con-
       minish., ren./hepat.impairm., elderly.  und.strict medic.supervis., mix.with insul.of anim. origin not stud.,   trol/ long-stand.diab., incr.insul.requirem.with infects.& fev., poss.
       Drug interactions: Oral antidiabet.agents/ACE-inhibit./disopyra-  mix.with human isophane insul. not recomm., take precaut.to avoid   dos.changes with concom.kidn./liv/ adren./ pituit & thyroid dis., re-
       mide/fibrates/fluoxetine/ MAOI/, pentoxifylline/propoxyphene/sa-  hypoglycaem. whilst driv., concom.dis./meds. which may delay   covery from hypoglycaem. poss.delay., should not be used for sev.
       licylates & sulfonamide antibiot.may enhanc.bld.gluc.low. eff., corti-  food absorpt., reqm.poss.incr.by illn.esp.infects., reqm.poss.decr.  hyperglycaem.treatm., med.supervis.if transf. to other insul.types/
       coster./danazol/diazoxide/diuret./ glucagon/ isoniazid/oestrog./pro-  by imp.ren./hepat. funct.  brands/manufact., CHF report. with concom.thiazolidinediones esp.
       gestog./ phenothiaz. deriv./ somatropin/sympathomimet.& thyroid   Drug interactions: Oral hypoglycaem.agents/ octreotide, MAOI’s/  if CHF risk fact.pres., observ.pt for S&S of CHS/weight gain/ oed.
       hormon. may reduc.bld.gluc.low.eff., ß-block./ clonid/Li & alcohol   non-select.ß-adrenerg.block. agents/ACE inhibit./salicylat./alcoh.&   with concom. thiazolidinediones, discont. concom. thiazolidinedi-
       may either potent.or weak. bld.gluc.low. eff., pentamid.may cause   anabol. ster.poss.reduc.insul.requirem., OC’s/thiaz./ glucocortic./thy-  ones if any sign of card. funct. deteriorat.occurs, safety & effic.not
       hypoglycaem. follow.by hyperglycaem., signs of adrenerg. counter-  roid hormon./sympathomimet.& danazol poss.incr.insul.requirem.,   investig. in childr./adolesc., revers.ophthalmolog.refract. disord./
       regulat.reduc./absent und. influence of sympatholyt.  beta-block.may mask hypoglycaem.sympts & delay hypoglycaem.   worsen.of diabet.retinopathy & ac.painf. periph. neuropathy assoc.
                                                                  with intensificat./rapid gluc. control improvem., rotate inj.sites to
       LEVEMIR, Novo Nordisk         recovery, alcoh.intensif.& prolongs hypoglycaem. eff.  reduc. lipodystrophy risk, do not add to infus.fluids/ mix. with other
       Insulin detemir (recombin.DNA technology in Saccharomyces   OPTISULIN, Sanofi-Aventis  medicin.prod., elderly, ren./hepat. impairm.,
       cerevisiae)                   Insulin glargine, correspond.to 100 U human insulin/ml.  Interactions: CHF report.with thiazolidinediones, oral antidiabet.
       Indications: Diab.mellit.     Indications: Diab.mellit.in adults, adolesc.& childr. ≥ 6 yrs where   meds./GLP-1 recept.agon./MAOI/ beta-block./ACE inhibit./salicy-
       (S3) SOL FOR INJ, 38/21.1/0084. 100 U/ml  insulin treatm.reqd.  lates/anabol.ster & sulphonamides may reduc.insul.requirem.,
       705313-001: 5x3 ml penfill cartr, R515,21  (S3) SOL.FOR INJ, 41/21.1/0363. 100 U/ml  OC’s/ thiazides/glucocorticoids/thyroid horm./ sympathomimet/
       705312-001: 5x3 ml dispos. Flexpen/Innolet device, R887,43  721502-001: 5x3 ml (SoloStar dispos.pen), R603,61  growth horm & danazol may incr. insul.requirem., beta-block.poss.
       Dosage: Indiv. Admin.SC 1-2xdly. For 2xdly. regim. admin.even.  723474-001: 5x3 ml cartr.for use with reuseable (AllStar pen),   mask hypoglycaem. sympts.& reduc.body’s response, octreotide
       dos.with even.meal/at bedt. /12 hrs. aft. morn.dos. Dos & admin.  R515,20.  & lanreotide may incr./decr.insul. requirem., alcoh.intensif./reduc.
       timing may need adjustm when transf.pts.form other antidiabet.   Dosage: Indiv.  insul.hypoglycaem. eff.
       treatm./incr.physic.activ./diet change/ concom.illn. Close gluc.  Contraindications: Safety & effic.not est.in childr.&lt; 6 yrs old, dia-
       monit.essent.                 bet.ketoacidos., no info on use in pregn.& lactat.  TOUJEO, Sanofi-Aventis
       Contraindications: IV admin., do mix.with other insulins, use in   Side effects: Hypoglycaem., poss.vis.impairm. with mark.change   Insulin glargine.
       insul.infus.pumps, do not add to infus.liq.  in glycaem.contr., lipohypertrophy/ lipoatrophy, loc.reacts., allerg.   Indications: Diab.mellit.in adults
       Side effects: Hyper-/hypoglycaem., trans.oed.& refract. anomal.,   reacts., insul.antibod.product., rarely sod.retent.& oed.  (S3) SOL.FOR INJ, 49/21.1/1230. 300 U/ml
       loc.hypersens.reacts., lipodystrophy if inj.sites not rotat., potent.life   Warnings and special precautions: Prolong. act.depend.on SC   723815-001: 3x1,5 ml dispos.pen, R538,52
       threat.gen. hypersens.reacts.  inj., rotate inj.sites, IV admin. could result in sev.hypoglycaem., do   Dosage: U not the same as IU/U used to express potency of other
       Special precautions: Elderly, ren./hepat. impairm., monit.poss.  not dil/mix. with other insul., see lit.regard.change over from oth-  insul.analog. Admin SC once dly.at any time of the day but pref.
       hyperglycaem.with inadeq. dos./treatm.discont., warn.signs of   er insulin(s), metabol.monit.recomm.dur. changeover & init.wks.  the same time every day. Make change in dos.caut.& only und.
       hypoglycaem. poss.change, concom.illn./infect., transf.pts to other   thereaft., pres.of insul. antibod. may req.dos.adjustm., where hy-  medic. supervis.
       types/brands, no clinic.exper.dur.pregn.& lactat., no diff.betw.hu-  poglycaem. episod.of clinic.signific., circumst. where warn.sympts.  Type 1 diab.mellit: Indiv.once dly.with meal-time insul.
       man insul.& insul.detemir regard. embryotox/teratogenic.reveal.   of hypoglycaem.diminish., pt. to take precaut.avoid.hypoglycaem.if   Type 2 diab.mellit: Recomm.start.dos: 0,2 U/kg once dly. follow.
       dur.anim. reproduct.stud.     driving, ren./ hepat.impairm., elderly.  by indiv.dos.adjustm.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page323.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page319.html">319</a>&nbsp;&nbsp;&nbsp;<a href="page320.html">320</a>&nbsp;&nbsp;&nbsp;<a href="page321.html">321</a>&nbsp;&nbsp;&nbsp;<a href="page322.html">322</a>&nbsp;&nbsp;&nbsp;<a href="page323.html">323</a>&nbsp;&nbsp;&nbsp;<a href="page324.html">324</a>&nbsp;&nbsp;&nbsp;<a href="page325.html">325</a>&nbsp;&nbsp;&nbsp;<a href="page326.html">326</a>&nbsp;&nbsp;&nbsp;<a href="page327.html">327</a>&nbsp;&nbsp;&nbsp;<a href="page328.html">328</a>&nbsp;&nbsp;&nbsp;<a href="page329.html">329</a>
             </td>
             <td width="35%"><a href="page325.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page325.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
